

REGULATORY PROGRAMME FOR CONTROL OF RESIDUES IN FOOD

COUNTRY	URUGUAY		DATE
YEAR OF PLAN IMPLEMENTATION	2021		
ANIMAL SPECIES / PRODUCT	BOVINE		
National PRODUCTION DATA - number of animals (referring to the previous year)	2.006.548		EU EXPORT DATA in number of animals (referring to the previous year)
PRODUCTION DATA for calculation of SAMPLE NUMBERS. (Number of animals (referring to previous year's production)	2.006.548		See Instruction sheet, note 4. If a split system is in place, no split system, and all animals are eligible for export
NUMBER OF SAMPLES	ACCORDING TO EU REQUIREMENTS		ACCORDING TO CODEX ALIMENTARIUS
MINIMUM	8026		
PLAN	8278		

GROUP OF SUBSTANCES TO BE MONITORED		NUMBER OF SAMPLES				COMPOUND or MARKER RESIDUE
		FARM	SLAUGHTER	TOTAL	TOTAL	
		MIN	MIN	MIN	PLAN	
A1	STILBENES	418,0	418,0	836	836	DES HEXOESTROL DIENOESTROL
A2	THYROSTATS	418,0	418,0	836	418	METILTURACIL PROPILTURACIL TIOURACIL FENILTURACIL TAPAZOL
A3	STEROIDS (WITH ANDROGENIC, ESTROGENIC OR PROGESTAGENIC ACTIVITY)	418,0	418,0	836	836	NORTESTOSTERONE TRENBOLONE BOLDENONE METHYL TESTOSTERONE
A4	RESORCYLIC ACID LACTONES	418,0	418,0	836	836	

						ZERANOL
A5	BETA AGONISTS	418,0	418,0	836	836	ZILPATEROL CLENBUTEROL SALBUTAMOL RACTOPAMINE MABUTEROL CINBUTEROL TERBUTALINE BROMBUTEROL CLENPENTEROL TULOBUTEROL MAPENTEROL
A6	e.g. Chloramphenicol + Nitrofurans+ Nitroimidazoles	418,0	418,0	836	836	
	Chloramphenicol				300	CHLORAMPHENICOL
	Other A6 substances				300	NITROFURANS AND METABOLITES SEM AOZ AMOZ AHD
					236	2HYDROXYMETHYL 1METHYL 5NITROIMIDAZOLE DIMETRIDAZOLE HYDROXY IPRONIDAZOLE HYDROXY METRONIDAZOLE IPRONIDAZOLE METRONIDAZOLE RONIDAZOLE
GROUP OF SUBSTANCES TO BE MONITORED		NUMBER OF SAMPLES		COMPOUND or MARKER RESIDUE		
		MIN	PLAN			
						ERYTHROMYCIN TYLOSIN SPIRAMICYN TILMICOSIN NEOMYCIN GENTAMICIN

B1	ANTIBACTERIAL SUBSTANCES	1204	1480	700	STREPTOMICYN SPECTINOMICYN				
					PENICILLIN V PENICILLIN G CLOXACILLIN CEPHALEXIN CEFTIOFUR/ DESFUROYLCEFTIOFUR AMPICILLIN AMOXICILLIN				
					OXYTETRACYCLINE CHLORTETRACYCLINE TETRACYCLINE DOXYCYCLINE				
				550	CIPROFLOXACIN-ENROFLOXACIN NORFLOXACIN DANOFLOXACIN MARBOFLOXACIN				
					FLORFENICOL/FLORFENICOL AMINE				
					SULFADIAZINE SULFATHIAZOLE SULFAMERAZINE SULFAMETHAZINE SULFACHLORPYRIDAZINE SULFAMETHOXAZOLE SULFADIMETHOXINE SULFAQUINOXALINE SULFAMETHOXYPYRADIZINE				
				30	OLAQUINDOX CARBADOX				
				B2a + B2b + B2c + B2d + B2e + B2f		1505	1700		
				B2a	ANTHELMINTICS		870	70	RAFOXANIDE CLOSANTEL
								600	IVERMECTIN DORAMECTIN MOXIDECTIN ABAMECTIN EPRINOMECTIN
								200	ALBENDAZOLE / ALBENDAZOLE SULFOXIDE/ALBENDAZOLE 2 AMINOSULFONE ALBENDAZOLE 2 AMINOSULFONE FENBENDAZOLE / FENBENDAZOLE SULFONE

					MEBENDAZOLE OXFENDAZOLE TRICLABENDAZOLE/TRICLABENDAZOLE SULFOXIDE LEVAMISOLE
B2b	ANTICOCCIDIALS		130	100 30	MONENSIN SALINOMYCIN NARASIN LASALOCID
B2c	CARBAMATES		30	30	ALDICARB SULFONE ALDICARB SULFOXIDE ALDICARB 3 HYDORXYCARBOFURAN CARBOFURAN CARBARYL
	PYRETHROIDS		450	450 450	CYPERMETHRIN PERMETHRIN DELTAMETHRIN FIPRONIL - FIPRONIL SULFONE FLUAZURON
B2d	SEDATIVES		80	80	XYLAZINE CHLORPROMAZINE AZAPERONE ACEPROMAZINE AZAPEROL
B2e	NON STEROIDAL ANTI-INFLAMMATORY DRUGS		80	80	METAMIZOLE (4 aminomethyl antipyrine) FLUNIXIN PHENYLBUTAZONE/OXYPHENBUTAZONE DICLOFENAC MELOXICAM
B2f	Other pharmacologically active substances		60	30	DEXAMETHASONE BETAMETHASONE PREDNISOLONE METHYLPREDNISOLONE FLUMETHASONE

				30	AMITRAZ
GROUP OF SUBSTANCES TO BE MONITORED		NUMBER OF SAMPLES			COMPOUND or MARKER RESIDUE
		MIN	PLAN		
B3a + B3b + B3c		301	500		
B3a	ORGANOCHLORINE COMPOUNDS INCLUDING PCBS				HCB
					HCH α
					HCH β
					LINDANE
					ALDRIN
					DDT AND METABOLITES
					DIELDRIN
					ENDRIN
					HEPTACHLOR
					HEPTACHLOR EPOXIDE
					ENDOSULFAN
					ENDOSULFAN SULFATE
					CHLORDANE cis-trans
					PCB 28
					PCB 52
					PCB 101
					PCB 118
	PCB 138				
	PCB 153				
	PCB 180				
B3b	ORGANOPHOSPHORUS COMPOUNDS		200		FIPRONIL - FIPRONIL SULFONE
					FLUAZURON
					ETHION
					DIAZINON
					CHLORPYRIFOS
					METHYL PARATHION
					PARATHION (ETHYL)
					PYRIMIPHOS METIL
					CHLORPYRIFOS METHYL
					ACEPHATE
					AZINPHOS METHYL
					DIMETHOATE
	MALATHION				
	MALAOXON				
	FENTHION				
	PHOSMET				

					COUMAPHOS
					TRICHLORFON
					NAPHTALOPHOS
B3c	CHEMICAL ELEMENTS		300	200	LEAD
					CADMIUM
				100	ARSENIC
					MERCURY

(*1) The level of action considers the MRL corrected by the uncertainty value associated with the analytical methodology

(*2) The levels of detection are under revision. A new analytical methodology based on GC MSMS is under development

K.L.M.: KIDNEY, LIVER, MUSCLE

Check calculation of total of minimums

8026

The minimum number of animals to be checked each year for all kinds of residues and substances must at least equal 0,4 % of the bov

Group A: 0,25 % divided as follows:

- one half of the samples are to be taken from live animals on the holding; (by derogation, 25 % of samples analysed for the research o
- one half of the samples are to be taken at the slaughterhouse.
- Each sub-group in Group A must be checked each year using a minimum of 5 % of the total number of samples to be collected for Gr
- The balance must be allocated according to the experience and background information of the country.

Group B: 0,15 % divided as follows:

- 30 % of the samples must be checked for Group B 1 substances.
- 30 % of the samples must be checked for Group B 2 substances.
- 10 % of the samples must be checked for Group B 3 substances.
- The balance must be allocated according to the situation of the country.

In order to facilitate this breakdown and ensure that the correct number of samples are tested, the spreadsheet has made the following way: - Of the samples to be tested for in Groups A1 - A6, one sixth of the total Group A samples are allocated to e B, 40% of these have been allocated to Group B1, 50% to Group B2 and 10% to Group B3.

mar-21



For exports to the EU, **actual export data** may be entered in this cell. If there is **no data for exports to the EU, national production data** must be entered in this cell

OTHER

MATRIX ANALYSED	SCREENING METHOD	CONFIRMATORY METHOD	SCREEN.METH. DETECTION LIMIT [µg/Kg]	CONFIR.METH. DETECTION LIMIT [µg/Kg]	LEVEL OF ACTION (i.e. concentration above which a result is deemed non-compliant) [µg/Kg] (*1)
URINE		GC/ MS		0,57 (*2)	0,57 (*2)
URINE		GC/ MS		0,58 (*2)	0,58 (*2)
URINE		GC/ MS		0,65 (*2)	0,65 (*2)
THYROID		HPLC/MS-MS		2,3	10
THYROID		HPLC/MS-MS		1,3	10
THYROID		HPLC/MS-MS		2,3	10
THYROID		HPLC/MS-MS		2,0	10
THYROID		HPLC/MS-MS		1	10
URINE		GC/MS - HPLC/MSMS		0,25	0,25
URINE		HPLC/MSMS		0,30	0,30
URINE		HPLC/MSMS		0,30	0,30
URINE		HPLC/MSMS		0,50	0,50

URINE		GC/MS		0,84 (*2)	0,84 (*2)
URINE		HPLC/MS-MS		0,37	0,37
URINE		HPLC/MS-MS		0,01	0,01
URINE		HPLC/MS-MS		0,01	0,01
URINE		HPLC/MS-MS		0,02	0,02
URINE		HPLC/MS-MS		0,01	0,01
URINE		HPLC/MS-MS		0,02	0,02
URINE		HPLC/MS-MS		0,06	0,06
URINE		HPLC/MS-MS		0,01	0,01
URINE		HPLC/MS-MS		0,02	0,02
URINE		HPLC/MS-MS		0,01	0,01
URINE		HPLC/MS-MS		0,01	0,01

MUSCLE	ELISA	HPLC/MS-MS	0,07	0,05	0,05
MUSCLE		HPLC/MS-MS			
MUSCLE		HPLC/MS-MS		0,14	0,14
MUSCLE		HPLC/MS-MS		0,11	0,11
MUSCLE		HPLC/MS-MS		0,05	0,05
MUSCLE		HPLC/MS-MS		0,43	0,43
MUSCLE		HPLC/MS-MS		0,23	0,23
MUSCLE		HPLC/MS-MS		0,17	0,17
MUSCLE		HPLC/MS-MS		0,51	0,51
MUSCLE		HPLC/MS-MS		0,34	0,34
MUSCLE		HPLC/MS-MS		0,39	0,39
MUSCLE		HPLC/MS-MS		0,33	0,33
MUSCLE		HPLC/MS-MS		0,23	0,23

MATRIX ANALYSED	SCREENING METHOD	CONFIRMATORY METHOD	SCREEN.METH. DETECTION LIMIT [µg/Kg]	CONFIR.METH. DETECTION LIMIT [µg/Kg]	LEVEL OF ACTION (i.e. concentration above which a result is deemed non-compliant) [µg/Kg] (*1)
K. L. M.		HPLC/MS-MS		10	100 (Kidney)
K. L. M.		HPLC/MS-MS		2	100 (Kidney)
K. L. M.		HPLC/MS-MS		10	300 (Kidney)
K. L. M.		HPLC/MS-MS		20	300 (Kidney)
K. L. M.		HPLC/MS-MS		400	7200 (Kidney)
K. L. M.		HPLC/MS-MS		40	750 (Kidney)

K. L. M.		HPLC/MS-MS		50	1000 (Kidney)
K. L. M.		HPLC/MS-MS		40	4000 (Kidney)
K. L. M.		HPLC/MS-MS		5	50 (Kidney)
K. L. M.		HPLC/MS-MS		8	50 (Kidney)
K. L. M.		HPLC/MS-MS		5	300 (Kidney)
K. L. M.		HPLC/MS-MS		10	1000 (Kidney)
K. L. M.		Under development		---	400 (Kidney)
K. L. M.		HPLC/MS-MS		5	50 (Kidney)
K. L. M.		HPLC/MS-MS		5	50 (Kidney)
MUSCLE	ELISA (BIOCHIP)	HPLC/MS-MS	50	10	100
MUSCLE	ELISA (BIOCHIP)	HPLC/MS-MS	50	10	100
MUSCLE	ELISA (BIOCHIP)	HPLC/MS-MS	50	10	100
MUSCLE	ELISA (BIOCHIP)	HPLC/MS-MS	50	20	100
MUSCLE	ELISA (BIOCHIP)	HPLC/MS-MS	50	10	100
MUSCLE	ELISA (BIOCHIP)	HPLC/MS-MS	5	5	5
MUSCLE	ELISA (BIOCHIP)	HPLC/MS-MS	100	10	200
MUSCLE	ELISA (BIOCHIP)	HPLC/MS-MS	75	10	150
MUSCLE	ELISA (BIOCHIP)	HPLC/MS-MS	Under development	3,7	200
LIVER	ELISA (BIOCHIP)	HPLC/MS-MS	40	10	100
LIVER	ELISA (BIOCHIP)	HPLC/MS-MS	40	10	100
LIVER	ELISA (BIOCHIP)	HPLC/MS-MS	40	10	100
LIVER	ELISA (BIOCHIP)	HPLC/MS-MS	40	10	100
LIVER	ELISA (BIOCHIP)	HPLC/MS-MS	40	10	100
LIVER	ELISA (BIOCHIP)	HPLC/MS-MS	40	10	100
LIVER	ELISA (BIOCHIP)	HPLC/MS-MS	40	10	100
LIVER	ELISA (BIOCHIP)	HPLC/MS-MS	40	10	100
LIVER	ELISA (BIOCHIP)	HPLC/MS-MS	40	10	100
MUSCLE		HPLC/MS-MS		0,25	0,25
MUSCLE		HPLC/MS-MS		0,25	0,25
MUSCLE		HPLC/FLD		15	30
MUSCLE		HPLC/FLD		23	1000
LIVER		HPLC/FLD		8	100
LIVER		HPLC/FLD		6	100
LIVER		HPLC/FLD		6	100
LIVER		HPLC/FLD		8	20
LIVER		HPLC/FLD		8	1500
LIVER	ELISA (BIOCHIP)	HPLC/MSMS	50	15	1000
LIVER	ELISA (BIOCHIP)	HPLC/MSMS	10	2	200
LIVER	ELISA (BIOCHIP)	HPLC/MSMS	50	5	500

LIVER	ELISA (BIOCHIP)	HPLC/MSMS	50	2	2
LIVER	ELISA (BIOCHIP)	HPLC/MSMS	50	2	500
LIVER	ELISA (BIOCHIP)	HPLC/MSMS	100	10	250
LIVER	ELISA (BIOCHIP)	HPLC/MSMS	75	10	100
LIVER		HPLC/UV		2	50
LIVER		HPLC/UV		3	6
LIVER		HPLC/UV		2	7
LIVER		HPLC/FL		20	100
MUSCLE		HPLC/FLD		1,19	10
MUSCLE		HPLC/FLD		0,8	10
MUSCLE		HPLC/FLD		1,1	10
MUSCLE		HPLC/FLD		1,2	10
MUSCLE		HPLC/FLD		1,4	10
MUSCLE		HPLC/FLD		1,0	50
FAT		GC/ECD		15	200
FAT		GC/ECD		10	100
FAT		GC/ECD		20	50
FAT		HPLC/MS-MS		5	60
FAT		HPLC/MS-MS		500	7000
KIDNEY		HPLC/DAD		4,9	10
KIDNEY		HPLC/DAD		3,4	3,4
KIDNEY		HPLC/DAD		3,8	3,8
KIDNEY		HPLC/DAD		6,6	10
KIDNEY		HPLC/DAD		3,5	10
MUSCLE		HPLC/MSMS		5,5	100
MUSCLE		HPLC/MSMS		1,5	20
MUSCLE		HPLC/MSMS		0,43	0,43
MUSCLE		HPLC/MSMS		0,47	5
MUSCLE		HPLC/MSMS		1,8	20
LIVER		HPLC-MS/MS		0,12	2
LIVER		HPLC-MS/MS		0,11	2
LIVER		HPLC-MS/MS		0,28	10
LIVER		HPLC-MS/MS		0,38	10
LIVER		HPLC-MS/MS		0,05	1

FAT		GC/ECD		5,8	100
MATRIX ANALYSED	SCREENING METHOD	CONFIRMATORY METHOD	SCREEN.METH. DETECTION LIMIT [µg/Kg]	CONFIR.METH. DETECTION LIMIT [µg/Kg]	LEVEL OF ACTION (i.e. concentration above which a result is deemed non-compliant) [µg/Kg] (*1)

FAT		GC/ECD		10	25
FAT		GC/ECD		10	25
FAT		GC/ECD		10	25
FAT		GC/ECD		10	20
FAT		GC/ECD		5	200
FAT		GC/ECD		10	1000
FAT		GC/ECD		10	200
FAT		GC/ECD		10	50
FAT		GC/ECD		10	200
FAT		GC/ECD		10	200
FAT		GC/ECD		10	50
FAT		GC/ECD		10	50
FAT		GC/ECD		50	200
FAT		GC/ECD		50	200
FAT		GC/ECD		50	200
FAT		GC/ECD		50	200
FAT		GC/ECD		50	200
FAT		GC/ECD		50	200
FAT		GC/ECD		50	200
FAT		GC/ECD		50	200
FAT		GC/ECD		50	200

FAT		HPLC/MS-MS		5	60
FAT		HPLC/MS-MS		500	7000
FAT		HPLC/MS-MS		0,5	10
FAT		HPLC/MS-MS		5	500
FAT		HPLC/MS-MS		5	10
FAT		HPLC/MS-MS		15	15
FAT		HPLC/MS-MS		15	50
FAT		HPLC/MS-MS		5	10
FAT		HPLC/MS-MS		15	50
FAT		HPLC/MS-MS		10	20
FAT		HPLC/MS-MS		10	10
FAT		HPLC/MS-MS		5	10
FAT		HPLC/MS-MS		2	20
FAT		HPLC/MS-MS		2	20
FAT		HPLC/MS-MS		10	50
FAT		HPLC/MS-MS		15	100

FAT		HPLC/MS-MS		2	10
FAT		HPLC/MS-MS		5	10
FAT		To be developed in 2021		---	10
K. L. M.		AAS		50	500 (Kidney)
K. L. M.		AAS		100	1000 (Kidney)
K. L. M.		AAS		10	2000 (Liver)
K. L. M.		AAS		160	500 (Liver)

hens slaughtered the previous year, with the following breakdown:

of Group A 5 substances can be taken from appropriate material (feedingstuffs, drinking water, etc.)

Group A.

following calculations which distributes the balance of samples between each of the (sub) groups in the
each subgroup with half being taken on-farm and half at slaughterhouse. - Of the samples to be tested for Group

LABORATORY NAME
DILAVE
XENOBIOTICOS
DILAVE
DILAVE

DILAVE
DILAVE
DILAVE
DILAVE
XENOBIOTICOS
LABORATORY NAME

DILAVE
DILAVE / XENOBIOTICOS
DILAVE
XENOBIOTICOS
DILAVE
DILAVE
DILAVE

XENOBIOTICOS
XENOBIOTICOS
DILAVE
XENOBIOTICOS
XENOBIOTICOS
XENOBIOTICOS

XENOBOTICOS

LABORATORY NAME

DILAVE

DILAVE

DILAVE

DILAVE

p